How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
75
TMDX Quote, Financials, Valuation and Earnings
Last price:
$129.69
Seasonality move
:
29.03%
Day range:
$127.00 - $132.19
52-week range:
$62.07 - $156.00
Dividend yield:
0%
P/E ratio:
52.35x
P/S ratio:
8.95x
P/B ratio:
12.47x
Volume:
814.4K
Avg. volume:
693.4K
1-year change:
73.8%
Market cap:
$4.4B
Revenue:
$441.5M
EPS (TTM):
$2.48
Analysts' Opinion
-
Consensus RatingTransMedics Group, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $144.20, TransMedics Group, Inc. has an estimated upside of 11.27% from its current price of $129.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $114.00 representing 12.04% downside risk from its current price of $129.60.
Fair Value
-
According to the consensus of 10 analysts, TransMedics Group, Inc. has 11.27% upside to fair value with a price target of $144.20 per share.
TMDX vs. S&P 500
-
Over the past 5 trading days, TransMedics Group, Inc. has underperformed the S&P 500 by -4.81% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TransMedics Group, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TransMedics Group, Inc. has grown year-over-year revenues for 16 quarters straight. In the most recent quarter TransMedics Group, Inc. reported revenues of $143.8M.
Earnings Growth
-
TransMedics Group, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter TransMedics Group, Inc. reported earnings per share of $0.66.
Enterprise value:
4.5B
EV / Invested capital:
--
Price / LTM sales:
8.95x
EV / EBIT:
46.71x
EV / Revenue:
7.91x
PEG ratio (5yr expected):
0.32x
EV / Free cash flow:
37.15x
Price / Operating cash flow:
42.01x
Enterprise value / EBITDA:
36.94x
Gross Profit (TTM):
$341.1M
Return On Assets:
10.7%
Net Income Margin (TTM):
16.2%
Return On Equity:
33.29%
Return On Invested Capital:
11.55%
Operating Margin:
16.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $191.8M | $401.1M | $566.4M | $108.8M | $143.8M | |
| Gross Profit | $126.9M | $237.7M | $341.1M | $60.7M | $84.5M | |
| Operating Income | -$10.9M | $31.5M | $96M | $3.9M | $23.3M | |
| EBITDA | -$4.4M | $49.3M | $121.4M | $9.1M | $30.1M | |
| Diluted EPS | -$1.10 | $0.93 | $2.48 | $0.12 | $0.66 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $125.6M | $250.6M | $536.7M | $492.5M | $613M | |
| Total Assets | $131.1M | $274.9M | $689.2M | $785.6M | $946M | |
| Current Liabilities | $15.9M | $20.7M | $49.1M | $60M | $79.7M | |
| Total Liabilities | $52.6M | $87M | $562.8M | $575.7M | $590.8M | |
| Total Equity | $78.5M | $187.9M | $126.5M | $209.9M | $355.2M | |
| Total Debt | $35.1M | $66.3M | $513.7M | $515.6M | $516.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.4M | $37.4M | $178M | $6.9M | $69.6M | |
| Cash From Investing | -$154.9M | -$157.5M | -$57.3M | -$47.8M | -$7.6M | |
| Cash From Financing | $402.6M | $22.6M | $14.9M | $7.9M | $3.6M | |
| Free Cash Flow | -$165.4M | -$120.5M | $120.6M | -$41.3M | $61.9M | |
TMDX
Sector
Market Cap
$4.4B
$23.1M
Price % of 52-Week High
83.08%
47.19%
Dividend Yield
0%
0%
Shareholder Yield
-0.41%
-1.67%
1-Year Price Total Return
73.8%
-24.84%
Beta (5-Year)
2.059
0.502
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$135.26
200-day SMA
Buy
Level
$122.58
Bollinger Bands (100)
Buy
Level
117.05 - 137.23
Chaikin Money Flow
Sell
Level
-860.5K
20-day SMA
Sell
Level
$137.58
Relative Strength Index (RSI14)
Sell
Level
42.88
ADX Line
Sell
Level
23.17
Williams %R
Buy
Level
-88.2988
50-day SMA
Sell
Level
$134.15
MACD (12, 26)
Buy
Level
32.58
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Sell
Level
-1.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.6212)
Sell
CA Score
(Annual)
Level (-1.2203)
Sell
Beneish M-Score
(Annual)
Level (-1.3655)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.1769)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
Stock Forecast FAQ
In the current month, TMDX has received 7 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TMDX average analyst price target in the past 3 months is $144.20.
-
Where Will TransMedics Group, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that TransMedics Group, Inc. share price will rise to $144.20 per share over the next 12 months.
-
What Do Analysts Say About TransMedics Group, Inc.?
Analysts are divided on their view about TransMedics Group, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TransMedics Group, Inc. is a Sell and believe this share price will drop from its current level to $114.00.
-
What Is TransMedics Group, Inc.'s Price Target?
The price target for TransMedics Group, Inc. over the next 1-year time period is forecast to be $144.20 according to 10 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is TMDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TransMedics Group, Inc. is a Buy. 7 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TMDX?
You can purchase shares of TransMedics Group, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TransMedics Group, Inc. shares.
-
What Is The TransMedics Group, Inc. Share Price Today?
TransMedics Group, Inc. was last trading at $129.69 per share. This represents the most recent stock quote for TransMedics Group, Inc.. Yesterday, TransMedics Group, Inc. closed at $129.60 per share.
-
How To Buy TransMedics Group, Inc. Stock Online?
In order to purchase TransMedics Group, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get TMDX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TMDX
Sector
P/E ratio
52.35x
23.34x
PEG ratio
0.32x
-0.01x
P/B ratio
12.47x
1.72x
Price / LTM sales
8.95x
1.47x
Growth Metrics
TMDX
Sector
Revenue growth
32.24%
3.51%
Earnings growth
458.46%
9.09%
Revenue (5-year growth)
79.64%
6.15%
Earnings forecast
$0.37
-$0.19
Profitability
TMDX
Sector
Profitability FY 2024
$261.9M
$2.7M
Return on invested capital
11.55%
-33.62%
Return on assets
10.7%
-29.68%
Return on equity
33.29%
-39.33%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Jan
28
Balance Sheet
TMDX
Sector
Total cash
$466.2M
$25M
Short term investments
--
$23.9M
Total assets
$828.4M
$72.5M
Long term debt
$516.1M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Sell
45
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
59
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 31x
Alerts
Buy
86
PAHC alert for Feb 6
Phibro Animal Health Corp. [PAHC] is up 8.04% over the past day.
Sell
35
GDXU alert for Feb 6
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.26% over the past day.
Buy
68
KLIC alert for Feb 6
Kulicke & Soffa Industries, Inc. [KLIC] is up 3.45% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
